Roger Perl­mut­ter’s lat­est ‘re­tire­ment’ gig opens a door to the bustling Chi­na biotech scene

Roger Perl­mut­ter will be do­ing some glo­be­trot­ting for the next chap­ter in his long-run­ning bio­phar­ma bio — though the ac­tu­al trav­el part may be on hold through the pan­dem­ic.

Ear­li­er in the week, we learned that Perl­mut­ter, who stepped down from his post as head of R&D at the start of this year, has signed on as a sci­ence ad­vis­er to the Shang­hai-based CBC group, a promi­nent in­vest­ment group that’s been fos­ter­ing some of the big new biotech star­tups in Asia.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE